Biologic Therapy and Asthma

Ravi K. Viswanathan; William W. Busse

doi:10.1055/s-0037-1606218

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2018; 39(01): 100-114
DOI: 10.1055/s-0037-1606218

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Biologic Therapy and Asthma

Authors

Ravi K. Viswanathan

¹Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
William W. Busse

¹Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Abstract

Although airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in severe asthma, patient responsiveness to medication is incomplete, and risks for exacerbation are increased. The development of biologics, which target selected and specific components of inflammation, has been a promising advance to achieve asthma control in patients with severe disease. This article reviews the current biologics available and under development and how their use has affected asthma and which subpopulations appear to benefit the greatest.

Keywords

asthma - asthma management - biologics for asthma - T2-type inflammation

Full Text

References

References
1 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2006). Available at: http://www.ginasthma.com/ . Accessed June 1, 2017
2 Center for Disease Control and Prevention. Asthma Facts—CDC's National Asthma Control Program Grantees. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2013. . Available at: https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf . Accessed May 23, 2017
3 National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; National Heart, Lung and Blood Institute; 2007. . Publication no. 07–4051. Available at: http://www.nhlbi.nih.gov/guidelines/asthma.2007 . Accessed August 1, 2011
4 Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11 (12) 958-972
5 Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9 (03) 310-318
6 Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19 (08) 977-979
7 Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling? Current perspectives. J Allergy Clin Immunol 2011; 128 (03) 439-448 , quiz 449–450
8 Katial RK, Bensch GW, Busse WW. , et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017; 5 (2S): S1-S14
9 Lötvall J, Akdis CA, Bacharier LB. , et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127 (02) 355-360
10 Tabatabaian F, Ledford DK, Casale TB. Biologic and new therapies in asthma. Immunol Allergy Clin North Am 2017; 37 (02) 329-343
11 Muraro A, Lemanske Jr RF, Hellings PW. , et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016; 137 (05) 1347-1358
12 Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res 2017; 9 (01) 3-14
13 Boulet LP, Boulay ME. Asthma-related comorbidities. Expert Rev Respir Med 2011; 5 (03) 377-393
14 Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol 2013; 13 (01) 78-86
15 Fahy JV, Fleming HE, Wong HH. , et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155 (06) 1828-1834
16 Busse W, Corren J, Lanier BQ. , et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108 (02) 184-190
17 Solèr M, Matz J, Townley R. , et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18 (02) 254-261
18 Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111 (01) 87-90
19 Holgate ST, Chuchalin AG, Hébert J. , et al; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34 (04) 632-638
20 Bousquet J, Cabrera P, Berkman N. , et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60 (03) 302-308
21 Hanania NA, Alpan O, Hamilos DL. , et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154 (09) 573-582
22 Busse WW, Morgan WJ, Gergen PJ. , et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364 (11) 1005-1015
23 Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124 (06) 1210-1216
24 Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010; 104 (02) 188-196
25 Hanania NA, Wenzel S, Rosén K. , et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187 (08) 804-811
26 Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013; 132 (02) 485-486.e11
27 Maurer M, Rosén K, Hsieh HJ. , et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368 (10) 924-935
28 Kaplan A, Ledford D, Ashby M. , et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132 (01) 101-109
29 Saini SS, Bindslev-Jensen C, Maurer M. , et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135 (03) 925
30 Kaplan A, Ferrer M, Bernstein JA. , et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016; 137 (02) 474-481
31 Busse W, Buhl R, Fernandez Vidaurre C. , et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129 (04) 983-989.e6
32 Long A, Rahmaoui A, Rothman KJ. , et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014; 134 (03) 560-567.e4
33 Cox L, Lieberman P, Wallace D. , et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128 (01) 210-212
34 Harris JM, Maciuca R, Bradley MS. , et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res 2016; 17: 29
35 Cowan DC, Taylor DR, Peterson LE. , et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol 2015; 135 (04) 877-883.e1
36 Nolte H, Pavord I, Backer V. , et al. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respir Med 2013; 107 (05) 656-664
37 Green RH, Brightling CE, McKenna S. , et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360 (9347): 1715-1721
38 Currie GP, Syme-Grant NJ, McFarlane LC, Carey FA, Lipworth BJ. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy 2003; 58 (07) 602-607
39 Zeiger RS, Schatz M, Dalal AA. , et al. Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study. J Allergy Clin Immunol Pract 2017; 5 (01) 144-153.e8
40 Shardonofsky FR, Venzor III J, Barrios R, Leong KP, Huston DP. Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma. J Allergy Clin Immunol 1999; 104 (01) 215-221
41 Leckie MJ, ten Brinke A, Khan J. , et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356 (9248): 2144-2148
42 Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167 (02) 199-204
43 Flood-Page P, Swenson C, Faiferman I. , et al; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176 (11) 1062-1071
44 Haldar P, Brightling CE, Hargadon B. , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10) 973-984
45 Pavord ID, Korn S, Howarth P. , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380 (9842): 651-659
46 Ortega HG, Liu MC, Pavord ID. , et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371 (13) 1198-1207
47 Chupp GL, Bradford ES, Albers FC. , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5 (05) 390-400
48 Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125 (06) 1336-1343
49 Roufosse FE, Kahn JE, Gleich GJ. , et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131 (02) 461-467.e1 , 5
50 Rothenberg ME, Klion AD, Roufosse FE. , et al; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358 (12) 1215-1228
51 Wechsler ME, Akuthota P, Jayne D. , et al; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376 (20) 1921-1932
52 Gevaert P, Van Bruaene N, Cattaert T. , et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128 (05) 989-995.e1 , 8
53 Castro M, Zangrilli J, Wechsler ME. , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3 (05) 355-366
54 Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest 2016; 150 (04) 789-798
55 Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016; 150 (04) 799-810
56 Spergel JM, Rothenberg ME, Collins MH. , et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012; 129 (02) 456-463 , 463.e1–463.e3
57 Laviolette M, Gossage DL, Gauvreau G. , et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132 (05) 1086-1096.e5
58 Bleecker ER, FitzGerald JM, Chanez P. , et al; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2115-2127
59 FitzGerald JM, Bleecker ER, Nair P. , et al; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2128-2141
60 Nair P, Wenzel S, Rabe KF. , et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376 (25) 2448-2458
61 Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am 2004; 24 (04) 599-614 , vi
62 Hart TK, Blackburn MN, Brigham-Burke M. , et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130 (01) 93-100
63 Tomkinson A, Tepper J, Morton M. , et al. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 2010; 65 (01) 69-77
64 Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370 (9596): 1422-1431
65 Wenzel S, Ford L, Pearlman D. , et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368 (26) 2455-2466
66 Wenzel S, Castro M, Corren J. , et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388 (10039): 31-44
67 Simpson EL, Bieber T, Guttman-Yassky E. , et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375 (24) 2335-2348
68 Simpson EL, Gadkari A, Worm M. , et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016; 75 (03) 506-515
69 Blauvelt A, de Bruin-Weller M, Gooderham M. , et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10086): 2287-2303
70 Bachert C, Mannent L, Naclerio RM. , et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016; 315 (05) 469-479
71 Piper E, Brightling C, Niven R. , et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41 (02) 330-338
72 Brightling CE, Chanez P, Leigh R. , et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3 (09) 692-701
73 Corren J, Lemanske Jr RF, Hanania NA. , et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365 (12) 1088-1098
74 Hanania NA, Noonan M, Corren J. , et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70 (08) 748-756
75 Hanania NA, Korenblat P, Chapman KR. , et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4 (10) 781-796
76 Gonem S, Berair R, Singapuri A. , et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016; 4 (09) 699-707
77 Erpenbeck VJ, Popov TA, Miller D. , et al. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther 2016; 39: 54-63
78 Holgate ST, Noonan M, Chanez P. , et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011; 37 (06) 1352-1359
79 Wenzel SE, Barnes PJ, Bleecker ER. , et al; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179 (07) 549-558
80 Ying S, O'Connor B, Ratoff J. , et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005; 174 (12) 8183-8190
81 Gauvreau GM, O'Byrne PM, Boulet LP. , et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370 (22) 2102-2110
82 Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 2013; 14: 93
83 Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352 (9134): 1109-1113
84 Busse WW, Israel E, Nelson HS. , et al; Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178 (10) 1002-1008
85 Busse WW, Holgate S, Kerwin E. , et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188 (11) 1294-1302
86 Peters MC, McGrath KW, Hawkins GA. , et al; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016; 4 (07) 574-584